Dr. Lindberg is from the Georgetown University School of Medicine, Washington, DC. Drs. DiLorenzo and DeSimone are from the Department of Dermatology, MedStar Washington Hospital Center/Georgetown University Hospital, and the Department of Dermatology, Georgetown University. Dr. DeSimone is from the INOVA Schar Cancer Institute, Fairfax, Virginia.
Cutis. 2023 Jan;111(1):E19-E25. doi: 10.12788/cutis.0697.
Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL.
皮肤 T 细胞淋巴瘤（CTCL）是一种慢性皮肤癌。皮肤靶向治疗很少能完全清除病变，且经常复发。在本病例系列中，9 名 IA 期至 IVA2 期 CTCL 患者接受了局部（IL）治疗，用 5-氟尿嘧啶（5-FU）和咪喹莫特（IMQ）乳膏 5%每日治疗顽固斑块和肿瘤。所有 9 名患者均获得完全缓解（CR），无复发，无严重副作用。我们发现，联合局部注射 5-FU 和 IMQ 乳膏 5%每日治疗顽固斑块和肿瘤是一种耐受性良好、有效且持久的 CTCL 皮肤靶向治疗方法。
